Aurobindo Pharma Limited

AUROPHARMA.BO·BSE
Compare
1,646.50−13.50 (−0.81%)today
As of Oct 19, 12:27 PM IST · May be delayed up to 15 min · INR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close1,660.00
Open1,660.35
Day range1,644.101,679.95
52-week range994.351,679.95
Off day high−1.99%
Off 52-week high−1.99%
Volume5.08K
Avg. volume (3M)41.09K
Market cap957.75B
EPS (TTM)58.89
Forward P/E21.97
P/E ratio (TTM)27.96
Dividend yield0.33% (4.00)
Beta (5Y)—
Shares outstanding580.80M
Short interest—
Earnings dateAug 5, 2026
Analyst target—
Profit margin—
Univest·

Aurobindo Pharma Share Price Today Near Peak on Fundamentals

Aurobindo Pharma Share Price is Rs 1,703.85, up 1.05% today, and is trading near its all-time peak area with market capitalisation of Rs 97,014.47 Cr. The latest Univest data confirms the price event and places Aurobindo Pharma Share Price…

Machine Maker·Positive

Aurobindo Pharma Receives USFDA Approval for Perampanel Tablets

Machine Maker Aurobindo Pharma Receives USFDA Approval for Perampanel Tablets Aurobindo Pharma Limited has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Perampanel Tablets in strengths…

Kalkine India·Positive

Aurobindo Pharma Shares in Focus After USFDA Approval for Perampanel

Aurobindo Pharma Secures Final USFDA Approval Aurobindo Pharma Ltd. (NSE: AUROPHARMA) has received final approval from the US Food and Drug Administration for perampanel tablets, placing the company's shares in focus. The approval allows…

From articles in the 4Search news index.

In the news

36mentions in 30 days
36with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 36 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.